Biotech Startups

Vertero develops therapies for neurodegenerative diseases by targeting causative mechanisms in the peripheral nervous system rather than addressing symptoms alone. The company uses discoveries in microbiology, pharmacology, and neuroscience to create novel drug treatments for patients with unmet needs.

2 investors

Vertosa develops water-dispersible emulsion technology and active ingredients that infused product makers, such as beverage and edibles producers, use to formulate stable, homogeneous, and bioavailable products. It provides customized aqueous solutions sold in bulk as dosed active ingredients along with formulation and manufacturing support.

2 investors

Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates. The company serves patients with prevalent chronic diseases using artificial intelligence, genomics, and patient-derived experimental models.

2 investors

VIA produces 3-Methylanisole (3-MA), a synthetic aromatic biofuel, through proprietary engineered yeast fermentation that converts starch, sugar, and cellulosic sugars into the aromatic compound. The company serves fuel manufacturers and chemical producers seeking scalable bio-based alternatives to petroleum-derived aromatics.

2 investors

ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines. A UCL spin-out originally established as SomaServe in 2018, the company operates from facilities in Cambridge, UK.

2 investors

Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections. The company focuses on infections with high prevalence and severe illness potential, serving patients with unmet treatment needs across multiple viral categories.

2 investors

ViAqua Therapeutics develops RNA-based solutions to treat diseases in aquaculture, specifically targeting viral pathogens like White Spot Shrimp Virus in shrimp through oral feed application. The company serves aquaculture producers and works with animal nutrition and health sectors in Israel.

2 investors

Videra provides AI-powered technology that supports behavioral health clinicians by enhancing their capabilities and patient engagement to improve care delivery and outcomes. The platform serves behavioral health providers and healthcare systems, focusing on democratizing access to quality mental health care.

2 investors

ViewMind develops technology that provides objective, measurable data about brain function under cognitive stress to support clinical evaluation. The company's solution complements traditional biomarkers and imaging for healthcare providers.

2 investors

Nasdaq-listed clinical-stage immunology company in San Francisco developing hepatitis B/D antivirals and licensed T-cell engagers.

2 investors

Virion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.

2 investors

ViroCarb is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its leadership brings experience in early-stage biopharma, medical devices, and industrial R&D.

2 investors

Vistim is a company leveraging neuroscience and artificial intelligence to develop solutions in the healthcare and medical technology space, drawing on expertise from neurology, brain-computer interfaces, EEG manufacturing, and pharmaceutical development.

2 investors

VisusNano develops ophthalmic drug delivery products, focusing on treatments for ocular and eye diseases. The company combines expertise in drug delivery, ophthalmic surgery, and clinical trials to create products for eye-care patients.

2 investors

Vitarka Therapeutics develops ENDOPORE, a drug delivery technology designed to transport therapeutic molecules into cells to treat diseases including cancer. The company operates in the biotechnology sector, focusing on solving a key challenge in drug development by enabling treatment targets that previously could not be reached.

2 investors

Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.

2 investors

Vittoria develops immunotherapies, specifically CAR T-cell therapies, to treat difficult-to-treat diseases including cancers beyond B-cell types. The company focuses on expanding the scope and efficacy of CAR T-cell treatment for patients with limited therapeutic options.

2 investors

Vivifi Medical develops a minimally invasive device to treat the underlying causes of Benign Prostatic Hyperplasia (BPH) in patients. The company builds urological medical devices and operates with a bi-coastal presence in Houston (Texas Medical Center) and Portland, Oregon.

2 investors

VIVUS is a pharmaceutical company developing and commercializing therapies for patients with serious medical conditions and life-limiting diseases. The company advances innovative treatments through clinical development and commercialization expertise.

2 investors

VO Health is developing a blood test based on multi-omics molecular signatures to measure biomarkers related to human healthspan, performance, adaptation, and recovery. Founded by physician-scientists, it partners with performance establishments, clinics, clubs, and universities and operates a CLIA laboratory and proprietary biobank.

2 investors

2 investors

vTv Therapeutics is a biopharmaceutical company developing oral, small molecule drugs for diabetes and other chronic diseases. Its lead candidate, cadisegliatin, is a glucokinase activator in Phase 3 trials for treating type 1 diabetes.

2 investors

Walden Biosciences is a clinical-stage biotech company developing disease-modifying therapies that selectively target the kidney to treat the underlying drivers of kidney disease. Its pipeline aims to change the treatment landscape for patients with degenerative kidney diseases.

2 investors

Wanda Fish develops cell-cultivated seafood, with a flagship cultivated toro bluefin tuna product grown using cell culture and biotechnology methods. The company targets the sustainable food market as an alternative to wild-caught and aquaculture fish.

2 investors